Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb 6:8:12.
doi: 10.3389/fnins.2014.00012. eCollection 2014.

Kynurenines in CNS disease: regulation by inflammatory cytokines

Brian M Campbell  1 , Erik Charych  1 , Anna W Lee  1 , Thomas Möller  1
Affiliations
Review

Kynurenines in CNS disease: regulation by inflammatory cytokines

Brian M Campbell et al. Front Neurosci. .

Abstract

The kynurenine pathway (KP) metabolizes the essential amino acid tryptophan and generates a number of neuroactive metabolites collectively called the kynurenines. Segregated into at least two distinct branches, often termed the "neurotoxic" and "neuroprotective" arms of the KP, they are regulated by the two enzymes kynurenine 3-monooxygenase and kynurenine aminotransferase, respectively. Interestingly, several enzymes in the pathway are under tight control of inflammatory mediators. Recent years have seen a tremendous increase in our understanding of neuroinflammation in CNS disease. This review will focus on the regulation of the KP by inflammatory mediators as it pertains to neurodegenerative and psychiatric disorders.

Keywords: CNS disease; IDO; KAT; KMO; astrocytes; kynurenine; microglia; neuroinflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the kynurenine metabolic pathway. The kynurenine pathway is commonly segregated into two distinct branches that are regulated by KATs and KMO, as well as the availability of l-kynurenine within the brain. Additionally, kynurenine metabolism is regulated by a variety of proinflammatory mediators which impact enzyme expression levels, thereby altering substrate availability and metabolite formation favoring the KMO branch of the pathway under immune-related pathological conditions. TRP, tryptophan; 5-HT, serotonin; Kyn, kynurenine; KYNA, kynurenine acid; 3-HK, 3-hydroxykynurenine; AA, anthranilic acid; XA, xanthurenic acid; 3-HAA, 3-hydroxyanthranilic acid; QUIN, quinolinic acid; IDO, indoleamine-2,3-dioxygenase; KAT, kynurenine aminotransferase; KMO, kynurenine 3-monooxygenase; KYNU, kynureninase; HAAO, 3-hydroxyanthranilic acid oxidase; LPS, lipopolysaccharide; BCG, bacillus Calmette-Guerin; IFNs, interferons; TNF, tumor necrosis factor; IL, interleukin.
Figure 2
Figure 2
Regulation of IDO1 transcription by inflammatory signaling. IFN-γ-dependent IDO1 induction (middle). Canonical IFN-γ receptor signal transduction leads to (1) NF-κB- and STAT-1-dependent transcription of IRF-1, and (2) IRF-1- and STAT-1-dependent transcription of IDO1. Synergistic IDO1 induction (Left). IL-1β, LPS, and TNF-α enhance transcription of IFN-γ receptor in an NF-κB-dependent manner. TNF-α has been shown to synergistically enhance IFN-γ-dependent IDO1 transcription by promoting NF-κB- and STAT-1-dependent IRF-1 transcription (within dashed circle). IFN-γ-Independent IDO induction (Right). TLR4 stimulation by LPS leads to transcription of IDO1 by a mechanism that requires NF-κB and either p38 or JNK, but not IFN-γ. The 5′-flanking region of INDO, the gene encoding IDO1, contains two IFN-γ-activated sites (GAS) and two interferon-sensitive response elements (ISREs). One of the two GAS sequences and both ISRE sequences are required for IFN-γ-mediated IDO1 induction. The 5′ flanking region of INDO also contains at least one NF-κB binding site and several AP-1 binding sites, which may be required for IFN-γ-independent mechanisms of IDO1 transcription.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abbott A., Roberts B. M., Turner L., Campbell D. W., Schaffer C. L., Campbell B., et al. (2010). Inhibition of kynurenine aminotransferase II (KAT II) protects against ketamine-induced cognitive impairment and improves spatial working memory. Soc. Neurosci. Abstr. 472.18
    1. Acuna-Castroviejo D., Tapias V., Lopez L. C., Doerrier C., Camacho E., Carrion M. D., et al. (2011). Protective effects of synthetic kynurenines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Brain Res. Bull. 85, 133–140 10.1016/j.brainresbull.2011.03.008 - DOI - PubMed
    1. Agaugue S., Perrin-Cocon L., Coutant F., Andre P., Lotteau V. (2006). 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J. Immunol. 177, 2061–2071 - PMC - PubMed
    1. Akimoto H., Yamada A., Takikawa O. (2007). Up-regulation of the brain indoleamine 2,3-dioxygenase activity in a mouse model of Alzheimer's disease by systemic endotoxin challenge. Int. Cong. 1304, 357–361 10.1016/j.ics.2007.07.026 - DOI
    1. Alberati-Giani D., Ricciardi-Castagnoli P., Kohler C., Cesura A. M. (1996). Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J. Neurochem. 66, 996–1004 10.1046/j.1471-4159.1996.66030996.x - DOI - PubMed